NeoGenomics COO Buys $9.54 Options Amid Stock Slide – Insider Confidence Signals Possible Turnaround?

Insider Activity at NeoGenomics: What the Latest Deal Reveals

The most recent insider transaction at NeoGenomics Inc. – a $9.54‑priced purchase of 36,825 stock options by Chief Accounting Officer Greg Aunan on March 1, 2026 – arrives against a backdrop of heightened social‑media chatter (buzz ≈ 495 %) and a modest positive sentiment (+84). While the option grant itself is a standard vesting incentive, its timing and the broader pattern of insider activity raise several points for investors to consider.

1. A Pattern of Forward‑Looking Grants, Not Cash Flows

Aunan’s trading history shows a steady stream of option and restricted‑stock‑unit grants from 2023 to 2025, with cumulative options outstanding exceeding 85,000 shares. The March 2026 grant is consistent with the company’s long‑term equity‑compensation strategy: it aligns the COO’s interests with shareholders and rewards performance over a multi‑year horizon. Importantly, these options have zero immediate cash outlay and are fully vested only after the next three anniversaries, limiting any short‑term dilution pressure.

2. Insider Confidence Amid a Weak Stock Performance

NeoGenomics’ share price has slipped 23 % over the past month, falling from its 52‑week high of $13.74 to $9.65. Yet insiders continue to acquire new equity. Aunan’s concurrent purchases of common stock and restricted units earlier in February (6,323 shares and 6,323 units) suggest confidence in a near‑term turnaround. The company’s recent launch of the RaDaR ST platform, aimed at expanding molecular residual disease testing, is a potential catalyst that may justify the continued insider optimism.

3. Investor Takeaway: Volatility Is On the Menu, Growth Is In the Pipeline

For shareholders, the key risk is the company’s negative earnings and a P/E ratio of –11.81, indicating ongoing losses. However, the steady inflow of equity from top executives—especially the COO and CEO, each holding large option balances—signals a belief that the company’s pipeline and operational improvements will eventually turn the corner. Investors may view the March option grant as a bullish micro‑signal: insiders are willing to stake additional equity on the company’s future, even as the stock trades near its 52‑week low.

4. Aunan Greg D: A Profile of a Long‑Term Investor

Aunan’s transaction history paints the picture of a seasoned insider who balances short‑term liquidity with long‑term alignment. His February 2026 trades involved a modest sale of 1,875 shares, a purchase of 6,323 shares, and a sale of 6,323 restricted units, leaving him with 22,027 shares of common stock and 16,117 units outstanding. The cumulative option balance—36,825 (Mar 2026) + 28,662 (May 2023) + 26,978 (May 2024) + 31,163 (Feb 2025)—exceeds 121,000 shares, underscoring a deep, multi‑year commitment. Across the last four years, Aunan has repeatedly purchased options rather than selling shares, a behavior that suggests belief in the company’s long‑term value creation.

5. Market Context: A Company in Transition

NeoGenomics remains a niche player in the life‑sciences diagnostics arena, with a market cap of $1.29 billion and a modest P/B of 1.53. The company’s focus on residual disease testing and recent product launches provide a potential revenue lift, but the negative earnings trajectory and volatile share price underscore the inherent risk. Insider purchases—particularly of equity tied to performance milestones—can be read as a signal that the company’s leadership expects a recovery in the near future.

Bottom Line

The March 2026 option grant by Greg Aunan, while routine in structure, sits within a broader pattern of insider confidence that outpaces the current weak stock performance. For investors, the key takeaway is that NeoGenomics’ senior leadership remains committed to a long‑term upside, even as earnings remain negative. The company’s upcoming product rollouts and the sustained insider equity purchases suggest potential upside, but the valuation remains precarious. Investors should weigh the insider optimism against the company’s current financial fundamentals before deciding whether to increase or maintain their positions.